Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million).
The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs, Michel Pairet, a member of the board of managing directors at Boehringer Ingelheim, said in a Nov. 22 release.
Boehringer has a history with the Swiss biotech, including co-leading a $27 million funding round in 2020 to support the launch of clinical-stage activities. T3’s lead product, dubbed T3P-Y058-739, is currently being studied in a phase 1 trial for patients with advanced solid tumors.
T3P-Y058-739 was developed using T3’s protein delivery platform that repurposes the bacterial type III secretion (T3S) system so that live bacteria can be harnessed to deliver immune-modulating proteins to cancer cells and tumor micro-environments while avoiding healthy tissue. The bacteria can carry several immune-modulatory proteins, allowing for immuno-oncology combination therapies to be delivered in a single agent.
The cancer platform fits into Boehringer’s vision for boosting long-term remission rates among individuals with cancer, which currently only occur in 15% to 20% of patients, according to the Big Pharma. The company hopes to achieve its goal by combining complementary immuno-oncology platforms—such as T-cell engagers, oncolytic viruses and cancer vaccines—to expand the benefits of immunotherapy to more patients.
Back in March, the German company put down $10 million upfront in a deal with Covant Therapeutics to discover covalent candidates against an emerging cancer target.
Under Boehringer’s wing, T3—a 2015 spin-off from the Biozentrum of the University of Basel—will keep operating in Switzerland. While the companies said the acquisition could be worth up to $508 million, no other financial details were disclosed.
By Gabrielle Masson
Source: fiercebiotech.com
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.